Black Di­a­mond brings in ex-GSK CEO Bob In­gram to chart new path in pre­ci­sion on­col­o­gy

Black Di­a­mond Ther­a­peu­tics start­ed the year with a more than $200 mil­lion vault on­to Nas­daq and a clin­ic-bound al­losteric ther­a­py — and now, the young biotech has Glax­o­SmithK­line vet Bob In­gram to help pave its way.

In­gram is set to take the reins from Black Di­a­mond’s found­ing chair­man Brad Bol­zon, the com­pa­ny an­nounced on Tues­day. The Mass­a­chu­setts-based biotech was the first to launch out of Ver­sant’s Ridge­line dis­cov­ery en­gine in 2018, co-found­ed by David Ep­stein and Eliz­a­beth Buck, for­mer de­vel­op­ers of the can­cer drug Tarce­va. Bol­zon will re­main on the board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER